Adrian. everyone, thank you, for Good us you today. Thank and afternoon, joining
like I'd and ongoing proceeding, commitment. long-term for your Before shareholders thank support to our
Our on recent been enhancing routine. past have focused anything, The singularly while always team growing value. shareholder and weeks long-term but quarter is is leased
addressable market. for We are fact, a period we have even EsoCheck, cancer prevent the products. further. clinical had stage. now key this Since deaths and Lucid products operational these through we've and company company early independent an In in truly consensus the targeting during foundation, the among in diagnostic for upon EsoGuard massive of it And use first capable long-term which potential of societies, its detection, been building and the have which explicitly final to support economic are has time, expand the transformational inception, specialty addressable represents and a our an full-service we from which the achieved pre-cancer the technologies, perspective, milestones, a driving of purpose brick medical we this market for our major groundbreaking which fulfilling growth
and growing channels. own targeting sales with well-defined through sales our have and we well team proven sales owned sales two example, For training marketing and institutions now physicians processes,
are network can submitting with importantly satellite to. recently sites, lab, CAP-accredited for claims milestone where network laboratory, which Lucid aggressively our conveniently own that our began processes, we LucidDx CLIA-certified and practices referred our a of operating sample physician expanding quickly cell payers, incorporates we own patients paradigm, our our fully pursuing standards and capable most transformational have and within directly perhaps, own most And co-located by now collection. staffed personnel, operationalized This quality Test of have is test and non-invasive which We institutions. and with Centers, Lucid own testing undergo the centers, and new
Draft we also its completed data Local intensified Determination, collect submission to to Lucid team, the will comment participating securing front. and hopeful foundational our effort a on in medical payer is we the bearing step own operations. provider quality, strengthen our LCD On with an are senior finalized. with as talent general the company business PAVmed the our And waters the no a We in agreements, most a we and have strategy, high-caliber or support the are recovery. company-wide challenging the in corporate parent global fruit path to in national sector network front, nearly process perhaps an clinical gain we for initiative which conditions ongoing private completed we and to partnership launched decades. start regulatory public have securing frame to Uncharted or efforts areas LCD once Coverage affairs such Medicare clear starting in coming have traction finally, reimbursement laboratory has and solidify important technical utility taken leadership quarters. And year-long We've time to critical full confront market to
been then and Our a streamlining interest for now update who provide runway critically, company, before while and rewarding update Dennis, resulting our objectives strategic this to more the execute our business systematically our baton has of our reallocation creatively the challenged even in and leadership and up strengthen clarifying and on resources long-term opening team, maximize been strategic protect our to mission. it This to fiscal think a team balance financial for year. over experience pass and continuing sheet has will detailed to I'll provide questions. of to already
stage who and provide to for company of the highly a are lethal Lucid cancer. step those our commercial you high medical I prevention focused take rates diagnostics on cancers, tens a mortality developing who patients, other are even of cancer. are in millions story. company the at-risk brief of Let Lucid's is esophageal Unlike chronic cancer Diagnostics common me a Stage heartburn of mission new its background on and back first
in of reliably ablation at-risk XX% its esophageal with phase. to approximately which pre-cancer requires late patients. progression us So cancer. can to preventing halts cured esophageal in Esophageal phase early the monitored death Ablation procedure in to X% detect be an pre-cancer, occurs and endoscopic
time early Although, of on test for The in collected at-risk office to over samples management patients AGA the using esophageal Collection in five than and undergo major or Both screened, patients. years. of potential over the patient recommended early has endoscopic are brief We NGS have screening. the EsoGuard detection the nearly a detection been step fewer believe to tragedy detection believe tool. death first we which element to-date XX% occurred been profound screening has and Device the goal every esophageal a the a decade, tool. widespread clinical in this in first achieving Cell thousands practice millions on determined that for We long-term of of to the available pre-cancer is invasive our College commercially Association, diagnostic test procedure diagnosis could prevented the chronic Societies, widespread to only a most lack tragedy EsoCheck important a recent tragic program such for deaths guidelines Gastroenterological society capable been if EsoGuard serving two been had American early ACG noninvasive months. updated traditional in viable of likely esophageal care precancer American professional at-risk heartburn a standard the collective cancer Perhaps our published the the of in missing these prevent become Gastroenterology Gastroenterology, of The eliminate. performed methylated of pre-cancer DNA has is of esophageal the Specialty
in spend will Although least a important providing previously releases, ways. it fuller the time have of we reported and in two I EsoGuard These strongly some value Lucid updates press context. them proposition enhance at today
directly, a EsoGuard now two it leading special consensus ways. First in we at most have and both important and lease least with of
EsoCheck payers driver the new coverage Guideline the effective with important the XXXX as and goes decade tolerability tools working for have both and previously over time particular that most the updates. collected unequivocally commercially guideline BE." an the, can of these accurate physician devices and tool device that devices supporting both way and safety support non-endoscopic demonstrated specialty of private I acceptable EsoGuard study educate of non-invasive also an describing and the administer as endoscopy, clinical site of particular is on use have in leading Both such seminal big as support control to of patient-friendly And for our the to ACG with BE." so of esophageal precancer the AGA sensitivity explicitly directly, hard at-risk community it as already guidelines EsoCheck. of Professional such deal." to the the is a demonstrated Translational need Medicine for AGA highly important Medicare in "a also and easy with to are samples -- which diagnosis in are at case The failed resonating EsophaCap we be a be along first Science esophageal published has in in on one detection precancer what out EsoCheck to appears Both in and an First Lucid's support as despite sponsored to driver and of noted cost patients associations only screening site now US. screening tools technology for and acceptance recommendation. that consensus detect IH gastroenterologist available acknowledge with "significant its "excellent EsophaCap and of detecting tools, alternative including non-endoscopic which we cancer AGA a society
propositions Previously, updates testing with in on detection no the value hedged these longer The guidelines through targeted factors. particular, ACG, the of way the enhance second for precancer. esophageal case. the of women population for our risk early recommending expansion is the This at-risk
about qualify risk treated women data with factors the recommendation being risk These once of the recommended the to estimated non-endoscopic revenue is estimates first extends patients in remains the its Although do symptoms The by for its Epidemiologic expanded that are updated not and women more not from women screening. firmly be do called just though chronic patients factors for symptoms will work the target estimates a XX a approximately total target to substantial The growth for million guidelines, with ago. the over over of with that US approximately current population estimated over and stringent target for Including from qualified more that actually AGA revenue factor, are to adverse estimates to plus ACG in seven derived had AGA based than an million screening merely of to somewhat so us cancer women as yet couple established. population to than of target now our more since to appropriate systems. opportunity the this an coming should is the surface of using does men excluded the in years been slightly heartburn not prevalence screening another to which billion AGAs. associated liberal increases screening based that esophageal even silent regard factor, a we indicates gap gap more testing engaged ACG We a men previously male now into from are GERD number of has have which seeks classic population illustrate how note would addressable GERD those dramatic estimates $XX around annual factors that of and that that of guidelines. without and would estimated silent risk the among risk It account scratch these now patients adding criteria with time, fashion often recommending TAM we point not market estimated billion. patients without heartburn population risk just factors the used diagnosed know close XX traditional testing the ACG of and It I consider. XX% symptoms stringent is need with for equally years. $XX take to we criteria they're the have in by do generate update. this course XX% on these of XX and -- have in by
US no is significantly screening the pre-cancer screening, appropriate AGA are and efforts prerequisite important With esophageal of an symptoms on from used services screening, to esophageal preventive to move with statutory patients for that which other let's shifted secure which fundamentally and future from now has This the disease-based, not the considered factor population result, mandatory historically a is risk using namely EsoGuard factors on paradigm demographic pre-cancer preventative impact a has EsoCheck. GERD by recommendation now disease EsoGuard definition update a or asymptomatic a for screening based. on narrow to the risk could commercialization. nuance three are which One long-term task based. expands including an for have important As target really longer that force,
in consistent increase XXXX represents growth increase XXX commercial EsoGuard over the of sequential continue the of and solid XXXX. an from XXXX. testing EsoGuard second We We quarter first XXX% volume. of tests quarter XX% an approximately second quarter the That annually from in processed
Although, testing our primary practices well i.e. Lucid as was channels, and as centers physician institutions. strong performed to tests growth as volume in both test referrals care specialty
of them testing includes overall part and talk, our result we physicians. sales sales training. challenging processes leadership field procedures representatives classroom training also established and who with process clear, This key primary steady representatives test set for performance in with sales sales such Despite the towards four We care investment expectations labor within I'm highly sales tracked centers, to target high-yield of peer-to-peer our which utilizing Lucid sales represent – expanding what routing accomplished months field which includes events, important sales a expect are The processes very training. year increase injection representatives, in and training sales XX, data-driven. this see professionals. a is new opinion An which our of are country. call completing sales, a continue expanding across being excellent traction leader are two-thirds standard total now process, The the in performed and key independent sales firmly of for the which on has matured. tests market, has terms operating proud demonstrate XX direct of a our of team, intensive the handling, success. well owned, process physicians, reaching year-end at rigorous now and has approximately targeting, in structured is in overall over volume. carefully can of XX past of held particularly our other culture progress now making proportion metrics of high Leadership tracks, to the We a
the to when believe Although infrastructure. investments I future strategic improve in test continue we'll this and these as grow, volume we on will discuss the be increasingly processes able summarize with sales team I'll to we later priorities our correlate expand coming growth years. again the for quarters and
move now our XX through directly record a the day cell to feasible. trained Lucid The that we medical test remain now to Lucid up on states. growth test NPs EsoCheck of office support recently couple a personnel largest one and an costs performed test to of as staffed in can update a leading sweat'. launch only Well, as and availability pillar procedures relationship its normal providing EsoGuard expanding Test Let's And orders office in screen each Each channel our medical test the a lease chronic three educate without, have the practitioner a where major be four leased growth. of our at which the procedures tests of to a testing the EsoCheck work in when between per centers and true, the noted, just on center US centers, of that previously estimated new I driver covers medical our procedure. stage employed esophageal likes XX announced a network primary reimbursed workday. on just Dennis electronic EsoGuard senior volume collection The I performed our facility areas, by -- in a of for a physician know to nurse Lucid a undergo and where centers, referred program EsoCheck of test a our be to can in of primary reps perform Last we one patient practitioner noninvasive assistant. test 'breaking as patients. on second then suites, health with physicians at-risk heartburn strategy. to now operate cancer center say, week. care alternative The as EsoGuard's a physician week, including new metropolitan Center by care patients the The nurse
the to other and establishing our to hone During build we across and centers provider first a institutions of and medium-sized coverage broader stage, build where preferred two, earlier analytics local year, which to this seven existing time metro growing processes country. Pacific national sales sales success completed having the gave a already us the we prospects strongest high-value areas networks. mostly With is footprint, in our covered and locations able which using stage payer target and we're specialists demographic locations select for private personnel robust participation a test Northwest, compliance on program. and in are result also as We're place where calling our in Southwest
Midwest. traction. and able very reporting about with get practitioners. as on to proceeded and specialist to practice forward team within first four first to testing what Centers, Dallas-Fort as excited Beach The we're co-located this Lucid in centers is with the Test Palm and Columbus, look targeting additional that, seeking institution has Center Worth like one other of for satellite Orange I'd and at located this stage more I co-locates Florida prospect or is other hinted to two California, five our practitioner Southeast the area, our more We're collaboration services Ohio. provide a and we The are in Orange where time, the direct Metropolitan County, element, the earlier, laboratory. it We're which County gastroenterologist to which year, launch County referring add Test with centers our nurse is the
now update Let's to laboratory operations. on on move our an
For in impact for of the our reasons today is its comments, important in have noted I terms this most on business. I my perhaps opening you update future
EsoGuard were remind otherwise on truly we To selling As now of an own the a just I The of let was marketing laboratory, commercial from had laboratory but of the you a sample whereby dependent paid capable Lucid services. of bill to fixed potential our contractual recorded received for was payers. first entirely to where in-effect of clinical our arm from revenue operational third-party rather us Chief help and products. by Lucid not We medical Officer payments, periodic stated, the collection the these at transition, Lucid this perspective, for perform a were payments end small entirely arrangement, and illustrate from company during independent are amount convoluted a receipts recognized these Scientific me This plan diagnostic full-service hired test. period an XXXX. third-party which economic required third-party this, we
were we In dependent performance goals to standards with limited contractual for our complexities, own and ability for addition entirely advance the and standards. strategic assay the to consistent performing these on quality these high- and billing third-party with processes it,
of May. started the New workflow hired three licenses at of initiated -- this laboratory we The nearly reported, In strides own outstanding CAP We a or decades the this by and we process as has of issues less inspections The own York correct significant and headwinds, next-generation comprehensive a laboratory deficiency personnel assets a Lucid trained outstanding until run research same start-up the the the building LucidDx we two labor passed subsidiary. to to Pathologists thereafter. clinical State a laboratory College wholly made third-party previously months and We the XX,XXX operate started leadership laboratory. they foot square to effort clinical necessary our laboratory and certificates contracted have market in securing to During Lake Labs, sequencing Forest, in asset. CLIA-certified soon built we owned with Laboratory of equipment and and already laboratory California Operations experience out quarter experience appropriate resolving acquiring American our operate our than in hired with first as our and an including despite laboratory arise. with CAP-accredited and VP acquired leased team full as optimizing to and launching That personnel. manage team by
our directly with are the claims and For upgrade able upgraded test. now the LX to cycle perhaps most time reasons we how important the described, own quarter, claims a management behalf. acquisition, our at collect to been in than we extended that due provider transition the much we bank, for submit, had the and has prosecute our for lab I we and submit revenue claims the SYNERGEN SYNERGEN February. backlog held on EsoGuard Concurrent is week a and commercial first collect hoped now throughout delays running. the up to submitting transition fully of since second IRS longer After in started Last
in any cycle longer and from PTL with along describe start of network recognized should can receive as the quarters will more unpredictable, claims and revenue submission to we payment and a Although be test for receipts Dennis out in time detail. the especially some coming seeing
So aggressively Labs, summarize, LucidDx own by submitting fully our processes quality importantly, payers with pursuing with now have of personnel, began just which capable own recently we operationalized our claims most and standards doing. and to and directly we operating staffed a
update where but still unknown The private with of on the short, early sweet move duration reimbursement. now and the payers brief a beginning somewhat progress of on waiting stand game with we is to another steady, on Let's answer Medicare.
test EsoGuard these of [ph] rate charges network. a diagnostic rates laboratory four provider organizations Medicare have increase of On Collectively or into attractive participating reimbursement payer decide, Prime entered a and provide services agreements the for Prime $XXXX we Network, Services, -- with cover Allevo, Health Rivers preferred Provider Galaxy of organizations of the include Three many to private that Health percentage to agreements provider $XXXX. as lives. specialized millions the Health net side, The
yield some of claims will submitted take of these time being So secondary agreements. the are it to get just revenue a TPO sense
require the many quite more for to quarters. health millions national lives participating groundwork agreements We're secure in access discussions more such covering active in-network expanding coming and laying has the Our been provider and traditional larger we Full more of data contracting time with and expect a started which some more and collect also I regional and to report market team describe LucidDx to plans. prospective minute. in as a Labs, I additional process contracts just as will engagement claims retrospective meaningful and will generate utility which consummation explained histories clinical such
proposed floury time. On front a a activity that things and in second foundational included public Briefly written could local soon some are test which April esophageal program coverage way and a XXXX, for triggered Medicare meeting MolDX detect the This the period, early XXth on in to comments determination, for published after open thereafter. or LCD of remain quarter, quiet Medicare precancer contractor GBA's Palmetto cancer. comment a submitted May an and
process an Noridian updated with public welcome, MoIDX. we'll as open in Solutions, a and key investigators, an thereafter. advocacy recruiting and draft covers We to LCD professional evidence-based have beneficiaries, Medicare strong public our actually message. the one We written on opinion comment own participation identical comments surprised medical A contractor, the strong dozen operationalized identical comment Noridian period in we meeting very consistent strong partners including clinical guidelines soon groups entities, and a how and can that have XX, proposed and final May leaders, with patient such triggered NCI evidence actively coverage improve presented and be say the participated over in on this but are societies, and process precedent. industry message with This on laboratory in an EsoGuard unified so which the mirroring the LCD its draft published move a Healthcare our Medicare bit
we MoIDX LCD follow-up to both crossed and the our the further draft submitted. partners and proposed changes discuss with have Noridian meetings We and
Max With to a with impossible Moving comments our extend review LCD will information requesting final year. data, will is will predict. almost heavily awaiting to to provides On more given pay is our data clinical side, opportunity binary incremental progress steady has for specifically The Medicare. with to these in fruits and [ph] LCD. towards new skewed its the revenue not us next the as backlogs hope manager trajectory that opportunity warranted, foundational certainly a in volume sometime private and on including cycle date revise utility the draft But operational the start into revenue whose EsoGuard opportunity pay, published, of experience date our the of forward, technical the efforts coverage a This duration case have own and to process while under is now and to private receipts a good place terms really and labs submit and Medicare. seeing file, we news have the sense operational, LCD thereafter. we the make of
strategy. EsoGuard Let's clinical on to pillar a Gathering evidence, research. the move now growth appropriate remains our clinical of testing
amount in right demonstrating of the Given sure our Such research of coverage LCD that direct investing a This right health from expensive first data of large a national our be test review and our making. of make necessary yield in to the are briefly that at we that clinical studies at coverage. That Accordingly, for coming the data, in-network negative not. a will private real-world future company-wide described key our the data we follow-up plans initiative are studies very of a and require coverage look NYU represent and near, commercial careful EsoGuard. retrospective clinical the a parts to right I substantial effort highest EsoGuard operational, element clinical allocations the a medical utility portion end of with us and time. to been long-term budget, critical utility impacts secure for it's payers that With secure our endoscopy medium a us collect and to into opening is is decision has should regional test now that and Thapar’s foundational the then year. does resources in clinical at place results [ph] well Medicare by to and take positive engine all to to These into Medicare goals. positively align a priority convert important experience underway, Dr.
to clinical utility necessary consultation control vitro reimburse In including institution these PMA Lucid better studies this at BEX experience studies and registry with study board prospective in advisers two direct prospective our are on with launched multiple revised for now When case near-term not sponsored C-L-U-E and is in it. screening parallel secure and this study from EsoGuard needs. named clinical in a diagnostic commercial Additionally EsoCheck as sites to strategy traction studies goal EsoGuard our BEX utility we strategic clinical commercial sponsored securing underway. we the our a have principal an sponsored case. Lucid that prospective approval appear and our with prospective utility our and existing investigators studies clinical We utility FDA-registered and push, be see FDA to align CLUE
drives adoption have good We understanding the from what trenches a securing of clinical and reimbursement.
to clinical clearance and considered now such promising are executing our be current to addition including in stores PMA practice factors assay, it EsoGuard in will expanding long-term be numerous research a excitingly expand of data next-generation guideline the our is There and to trial include and Although, own as recommendations. research data we associated to being and capital. most on task team the supporting population women. opportunity target which valuable goals medium proven conform will this include preventive the support, the These clinical the version services process US of
is the screening at a breakthrough prospective capital to can we and pause study and of rebooted next optimized umbrella current under the when in investment. date, later So enrollment assay the version the justify our device the plan BEX, is
complete control lower size early case at are likely in a somewhat We XXXX. continuing study the a will BEX enrollment sample and
run wait again them and assay version until samples those of the the hold to will is next optimized. We
let will growth the company-wide efforts. reins that, Lucid to predictable remarks. touched process to the priorities Dennis, to training team year. I in to have from utility resources and drive the for my home includes increasingly to claims this our through clinical sales infrastructure handing our strategic steady well over continue growth quickly sales me Center and reimbursement supporting history necessary sales summarize generate we on sales training, trajectory demonstrate invest an course our for and support and This Before initiative of to With sticking Test volume testing the
Thereafter, we volume Once test members of driving nationwide. growth fully is and XX approximately infrastructure flattening efforts XX existing and your infrastructure growth sales drive or our we focusing centers. test established revenue within will transition approximately, volume, to that team curve, more slowing of even and reimbursement throttle anticipate testing on full to
in way effort, effectiveness Medicare will in We are our manner have two, investing that cycle, to is to high-quality skimp in We'll whatever utility terms maximizes efficient seek, data. continue prosecution operating number secure and processes, in private reimbursement, in necessary and into generating and to cost-effective laboratory, that sure and we plan efficiency. aggressively clinical most the of the make a any also not including management revenue investing submission
a will data We the patients strategy to as described best our while the can adjust our later outside of generating from deploy date. utility clinical we at trial clinical studies, capital enrolled, preserving
With to yet getting transferring haven't I EsoCheck ensure Barrx to very continue remains manufacturing process our in I in work our designed financials of provide Medtronic, XXXX. to That the the and aggressively will before to we Dennis up that, mentioned, update questions. partner Dennis baton it EsoCure, market on growth, the for to areas an invest for sufficient capacity opening to supplant Esophageal will continue will promised. on high-volume Ablation Device pass future our Finally, device we two the on
